SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Slides:

Advertisements

Similar presentations

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Advertisements

Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.

BIFURCATION LESIONS Dr. Tahsin.N

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.

(p for noninferiority = 0.01)

INFRATIBIAL INTERVENTIONS Current Results with DES

(DES)+BVS +DCB for long diffuse LAD disease

Strategy planning in coronary bifurcation stenting

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203

The Tryton Bifurcation Trial:

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Circ Cardiovasc Interv

Stenting of Coronary Arteries in Non Stress/Benestent Disease

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

TAXUS II and IV: two-year follow-up

Giuseppe Biondi Zoccai

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

Primary endpoint at 1 year

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Figure 2 Imaging of atherosclerotic plaque burden

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

3-Year Clinical Outcomes From the RESOLUTE US Study

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Presented at ACC 2003 Late Breaking Clinical Trials

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Randomized Comparison in the Setting of Acute MI

After Eighty Study Trial design: Elderly patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) were randomized to invasive therapy (n = 229)

Main branch restenosis at 1 year

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p = 0.32 for noninferiority)

(p < for noninferiority)

(p = for noninferiority)

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Presented at TCT 2006.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

MACE: Death, MI or TLR at 5 years

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

(p for non-inferiority < 0.001)

Glenn N. Levine et al. JACC 2011;58:e44-e122

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy (n = 130) for provisional treatment of side branch coronary arteries. Results (p = 0.97) Target vessel failure at 1 year: 9.4% of the conservative group vs. 9.2% of the aggressive group (p = 0.97) Target lesion revascularization (TLR) for main branch at 1-3 years: 0 in the conservative group vs. 8 in the aggressive group (p = 0.007) 9.4 9.2 % Conclusions Among individuals with a bifurcation coronary lesion, a conservative approach to provisionally treat the side branch was superior to an aggressive approach The difference in TVR was mainly due to a significant increase in main vessel TLR in the aggressive group Conservative approach Aggressive approach Song YB, et al. JACC Cardiovasc Interv 2016; 9:517-26